natgillin/translations-raw huggingface dataset:
A fan assembly as claimed in any preceding claim, wherein the silencing member (72) comprises acoustic foam. 
Ventilatorski sustav, gdje dio za stišavanje buke (72) obuhvaća akustičnu pjenu.
Compound (II) is obtained by cleavage of the Boc group from intermediate (9), by means of a hydrochloric acid solution (4N) in dioxane and isolating the free amine instead of the hydrochloride. 
Spoj (II) je dobiven cijepanjem Boc-skupine iz međuprodukta (9) pomoću klorovodično kiseline (4 M) u dioksanu i izolacijom slobodnog amina umjesto hidroklorida.
Freight container according to any one of the preceding claims, wherein the container is an intermodal container or a so-called multimodal transport container, especially an ISO container; and/or wherein at least the outer length of the freight container corresponds with the sizes and dimensions of a standard freight container, especially a 45 foot container; and/or wherein the freight container is formed as a 45 foot container, preferably as a so-called 45 ft. pallet wide container; and/or wherein the cargo floor (3) is at least 2.4 meter wide and at least 13.2 meter long, such as to accommodate at least 33 Euro-pallets; and/or wherein the container is provided with first fitting blocks of which the mutual spacing corresponds to the mutual spacing of a 40 foot container and/or second fitting blocks or so-called corner fittings of which the mutual spacing corresponds to the mutual spacing of the outermost placed fitting blocks of a 45 foot container. 
Teretni kontejner sukladno bilo kojem od prethodnih zahtjeva, čemu barem vanjska dužina teretnog kontejnera odgovara veličinama 1 dimenzijama standardnog teretnog kontejnera, osobito kontejnera od 45 stopa, ili pri čemu je teretni kontejner oblikovan kao kontejner od 45 stopa, preporučljivo kao takozvani kontejner čije su palete 45 ft. široke, ili pri čemu je pod (3) tereta širok najmanje 2,4 metara i dugačak najmanje 13,2 metara, tako da prima najmanje 33 Euro palete. Teretni kontejner sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu je kontejner dan sa prvim ugradim blokovima čiji međusoban razmak odgovara međusobnom razmaku kontejnera od 40 stopa i/ili drugim ugradim blokovima ili takozvanim kutnim elementima čiji međusobni razmak odgovara međusobnom razmaku najudaljenije postavljenih ugradih blokova kontejnera 45 stopa.
A composition comprising about 2 mg to about 25 mg of buprenorphine and a therapeutically effective amount of Compound-1, wherein Compound-1 has the structure: 
PATENTNI ZAHTJEVI zvonamaonR e Pripravak koji sadrži 1:1 maseni omjer buprenorfina prema Spoju- 1, pri čemu Spoj- 1 ima strukturu: nać
determining a level of human soluble Growth Stimulation-Expressed Gene 2 (ST2) in a sample comprising blood, serum, or plasma from a subject using an isolated antibody produced by the hybridoma deposited at the American Type Culture Collection (ATCC) and designated by Patent Deposit Designation PTA-10432, or an antigen-binding fragment of an antibody produced by the hybridoma deposited at the ATCC and designated by Patent Deposit Designation PTA-10432; and 
Izolirano antitijelo ili njegov antigen-vezujući fragment koji se specifično vezuje za humani solubilni stimulacijom rasta-eksprimirani gen 2 (ST2), gdje je antitijelo ili fragment proizveden pomoću hibridoma deponiranog u Američkoj zbirci tipova kultura (American Type Culture Collection - ATCC) i označen pomoću patentne oznake deponiranja PTA-10432.
• cardiovascular diseases, particularly hypertension, stenosis or restenosis of blood vessels, arteriosclerosis 
kardiovaskularnih bolesti, osobito hipertenzije, stenoze ili restenoze krvnih žila, arterioskleroze,
The method according to claim 9, wherein said additional integral action (A1; 49) is set proportional to a spring-constant or spring stiffness of said drill string (12) modelled as a torsional spring. 
Postupak sukladno zahtjevu 9, pri čemu je navedeno integralno djelovanje (Al; 49) prilagođeno proporcionalno konstanti opruge ili čvrstoći opruge navedene bušilice (12) modelirane kao torzijska opruga.
isolating bird embryo(s) at a developmental stage around oviposition, wherein said bird is selected in the order of Anseriformes and the genome of said bird does not contain endogenous proviral sequences susceptible to produce replication competent endogenous retroviral particles; 
izoliranje ptičjeg embrija u razvojnoj fazi oko ovipozicije, pri čemu se ta ptica izabire iz reda Anseriformes i genom te ptice ne sadrži endogene pro-virusne sekvence sklone proizvodnji za replikaciju kompetentnih endogenih čestica retrovirusa;
A fermentation process comprising the following steps: providing a sample of bacteria of a Bordetella species; incubating the sample of bacteria of a Bordetella species in a first culture medium in the presence of at least one bvg (bordetella virulence genes) modulator for at least 5 generations, thereby producing a mature culture, wherein the bvg modulator is selected from the group consisting of niacin, a magnesium salt, a sulphate salt, a phosphate salt, a carbonate salt, sucrose, proline, sodium ions at a concentration greater than 100mM, an antifoaming agent, glutathione, and a sulphur containing amino acid; 
PATENTNI ZAHTJEVI Fermentacijski postupak, naznačen time što obuhvaća sljedeće korake: a) = osiguravanje uzorka vrste bakterija iz roda Bordetella; b) inkubiranje uzorka vrste bakterija iz roda Bordetella u prvom mediju za kulturu, u prisutnosti najmanje jednog modulatora bvg (bordetelini geni virulentnosti) kroz najmanje 5 generacija, čime se dobije zrelu kulturu, gdje se modulator bvg bira iz skupine koju čine niacin, magnezijeva sol, sulfatna sol, fosfatna sol, karbonatna sol, saharoza, prolin, natrijevi ioni u koncentraciji većoj od 100 mM, sredstvo protiv pjenjenja, glutation, te aminokiselina koja sadrži sumpor;
The following starting materials were also prepared similarly to (b) above, starting from the appropriate N-substituted acetoacetates and ammonium acetate, and were used directly without characterisation:- 
Slijedeći polazni materijali također su spravljeni na sličan način s (b) gore, polazeći od odgovarajućeg N-supstituiranog acetoacetata 1 amonij-acetata, 1 korišteni su direktno bez karakterizacije:
The compound according to claim 1, wherein R2 is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocycloalkyl; optionally wherein R2 is heterocycloalkyl selected from the group consisting of substituted or unsubstituted oxanyl, substituted or unsubstituted oxetanyl, and substituted or unsubstituted morpholinyl. 
Spoj za uporabu prema zahtjevu 1, naznačen time što je R2 supstituirani ili nesupstituirani alkil, supstituirani ili nesupstituirani cikloalkil, ili supstituirani ili nesupstituirani heterocikloalkil; proizvoljno pri je čemu R2 heterocikloalkil odabran iz skupine koju čine supstituirani ili nesupstituirani oksanil, supstituirani ili nesupstituirani oksetanil, i supstituirani ili nesupstituirani morfolinil.
Thiazolidin-4-one derivatives according to any of claims 4 and 5 wherein R14 represents an unsubstituted, or a mono- or di-substituted phenyl group. 
Derivati tiazolidin-4-ona prema zahtjevima 4 i 5, naznačeni time, da R14 predstavlja nesupstituiranu, ili mono- ili di-supstituiranu fenilnu skupinu.
In accordance with achieving the foregoing objects of this invention, a compound is provided having formula (1) 
F Spoj naznačen time što ima formulu (1) i njegove soli i otopine.
The use of a nail varnish, normally a water insoluble polyvinyl resin film, can also decrease water loss: the disadvantage of that procedure is that the removal of the nail varnish by an organic solvent can further damage the nail structure by increasing brittleness and splitting. 
Upotreba laka za nokte, koji je obično vodonepropusan film od polivinilne smole, također može smanjiti gubitak vode: nedostatak ovog postupka je u tome što uklanjanje laka za nokte pomoću organskog otapala može dodatno oštetiti strukturu nokta povećanjem krhkosti i cijepanja.
Titanium tetrachloride C10 ml., 0.087 mole) was added dropwise to the resulting solution (vigorous reaction), with the reaction mixture stirred at below 10°C. during the addition peri.od. 
Doda se titan-tetrahklorid (10 ml., 0.087 mola) ukapavanjem na dobivenu otopinu (snažna reakcija), pri čemu se reakcijska smjesa miješa na ispod 10%C za vrijeme perioda dodavanja.
is difluoromethyl, Y is —CHR2—, and R2 is isopropyl; or a tautomer of such a compound; and component B) is a compound selected from the group consisting of azoxystrobin; picoxystrobin; cyproconazole; difenoconazole; propiconazole; fludioxonil; cyprodinil; fenpropimorph; fenpropidin; a compound of formula F-1 
MOO (D, pri čemu R, je difluorometil ili trifluorometil; Y je ili pe ==ZCH, a Ro je vodik ili C,-Csalkil; ili tautomer takvog spoja; te komponenta B) je spoj koji je odabran iz skupine koja sadrži Azoksistrobin; Pikoksistrobin; Ciprokonazol;
is administered in an amount of from about 200 mg/day to about 3000 mg/day, from about 1000 mg/day to about 2500 mg/day, from about 1700 mg/day to about 2100 mg/day or about 1920 mg/day; and 
se primjenjuje u količini od oko 200 mg/dan do oko 3000 mg/dan, od oko 1000 mg/dan do oko 2500 mg/dan, od oko 1700 mg/dan do oko 2100 mg/dan ili oko 1920 mg/dan; te
In some embodiments, the separation zone keeps most of the unreacted 1,1,1,2,3-pentachloropropane in the reaction zone, and allows most of the 1,1,2,3-tetrachloropropene product to escape the reaction zone. 
Postupak prema zahtjevu 9, gdje je temperatura reakcijske zone za dehidrokloriranje od 120 do 180"C, tlak zone odvajanja je u rasponu od 13 do 60 kPa (100 do 600 tora) i temperatura zone kondenzacije je takva da uzrokuje da se 1,1,2,3-tetrakloropropen destiliran iz reakcijske zone kondenzira u tekućinu.
aa) dissolving the compound of the formula (III) and/or (II): with a buffer; 
5 aa) otapanju spoja formule (III) i/ili (ID):
the height of the downstream portion being sufficiently large to facilitate passage therethrough of the blood cells and sufficiently small to inhibit passage therethrough of said selected cells, and 
Uređaj prema patentnom zahtjevu 1, pri čemu visina donjeg dijela sprečava prolaz cirkulirajućim stanicama tumora i olakšava prolaz crvenim krvnim zrncima čovjeka.
In Vivo Assay for Anti-Hyperglycemic Activity of Compounds of the Invention 
In Vivo ispitivanje anti-hiperglikemijskog djelovanja spojeva izuma
The clarithromycin, lactose, starch and Ac-Di-Sol were mixed in a 2.5 L high-shear VG5 Glatt granulator for 5 minutes with a impeller set at 300 rpm and chopper set at 2400 rpm. 
Klaritromicin, laktoza, škrob i Ac-Di-Sol se miješaju u 2,5 litarskom visoko-smičnom VG5 Glatt granulatoru tijekom pet minuta uz impeler namješten na 300 okretaja po minuti i uz rotacioni sjekač namješten na 2400 okretaja po minuti.
The method of claim 1, wherein the ActRIIa-Fc fusion protein is administered so as to reach a serum concentration in the patient of at least 1000 ng/mL. The method of claim 1, wherein the ActRIIa-Fc fusion protein has a serum half-life of between 15 and 40 days in normal, healthy humans. 
Farmaceutska smjesa iz bilo kojeg od prethodnih zahtjeva, naznačena time, što ActRIIa-Fc fuzijski protein ima poluživot u serumu, kod normalnih, zdravih ljudi, u prosjeku od 25 do 32 dana, i ekvivalentnu bioraspoloživost, kada se primjeni intravenski ili subkutano.
11 provides a schematic diagram of an alternative arrangement for connecting the receiver to an acoustic transducer, wherein the transducer is controlled by an external relay. 
Slika 11 je shematski dijagram alternativnog razmještaja za spajanje prijemnika na akustički davač, pri čemu se davač upravlja pomoću vanjskog sklopa.
and Y4 each represent, independently of each other, a CH group or a nitrogen atom, represents a C-X-Ar group and Y3 represents a nitrogen atom or a C-W group, or Y2 represents a nitrogen atom or a CH group and Y3 represents a C-X-Ar group, on the condition that: 
Yi i Ya svaki predstavlja, neovisno jedan od drugoga, skupinu CH ili dušikov atom, Y2 predstavlja skupinu C-X-Ar te Y3 predstavlja dušikov atom ili skupinu C-W, ili Y2 predstavlja dušikov atom ili skupinu CH te Y3 predstavlja skupinu C-X-Ar, uz uvjet da:
wherein A is at least one member selected from the group of —H, -halo, —OH, —C1-3 alkyl and —C1-3 alkoxy, and wherein -halo is selected from the group of -fluoro and -chloro. 
Formula Ila gdje je A najmanje jedan član izabran iz grupe koju čine -H, -halo, -OH, -Cisalkil i -C,salkoksi, i gdje je -halo izabran 1z grupe koju čine -fluoro i -kloro.
The resulting 2-phase-mixture is added to 50 ml ethyl acetate. 
Rezultirajuća dvo-fazna-smjesa se doda u 50 ml etil acetata.
Alkaline metal (e.g. Na) 1-13 phosphate(s) 
Fosfat (fosfati) alkalnih metala (npr., Na) 1-13 posebno:
A compound according to claim 1 for use in the treatment of conditions or disorders mediated by S1P1 receptors, wherein the condition or disorder is multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependent diabetes. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi u liječenju stanja ili poremećaja povezanih s receptorima S1P1, gdje je stanje ili poremećaj multipla skleroza, autoimune bolesti, kronični upalni poremećaji, astma, upalne neuropatije, artritis, presađivanje, Crohnova bolest, ulcerozni kolitis, eritematozni lupus, psorijaza, ishemijsko-reperfuzijska ozljeda, čvrsti tumori, te tumorske metastaze, bolesti povezane s angiogenezom, bolesti krvnih žila, bolna stanja, akutne virusne bolesti, upalna stanja crijeva, dijabetes ovisan i dijabetes neovisan o inzulinu.
* indicates a chiral centre which is in the (R) or (S) form; or pharmaceutically acceptable acid addition salts or in vivo cleavable esters thereof. 
* označuje kiralni centar, koji je u (R) ili (S) obliku; i njihove farmaceutski prihvatljive kisele adicijske soli ili esteri koje se može cijepati in vivo.
The composition of para 1, wherein the isolated monomeric platinum complex is (Trans -1,2-cyclohexanediamine)(dihydrogen pyrophosphato)platinum(II). 
Pripravak za uporabu u postupku liječenja raka prema zahtjevu 1, naznačen time da izolirani monomerni kompleks platine je (trans-1,2-cikloheksandiamin)(dihidrogen pirofosfato)platina(II).
Composition according to claim 1, wherein the red blood cells encapsulating a tumor antigen have been prepared by lysis-resealing in order to encapsulate the antigen. 
Pripravak za uporabu u skladu s bilo kojim od zahtjeva 1 do 12, naznačen time da su crvene krvne stanice koje inkapsuliraju tumorski antigen pripremljene pomoću liziranja-ponovnog zatvaranja.
X is hydrogen, substituted or unsubstituted lower alkyl, or substituted or unsubstituted lower heteroalkyl. 
(a) supstituirani ili nesupstituirani fenil ili supstituirani ili nesupstituirani naftil;
The fine white powder of small tetragonal crystal is transferred to a teflon beaker and suspended in 5 M KOH. 
Fini bijeli prašak malih tetragonskih kristala je zatim prenesen u teflonsku času i suspendiran u SM KOH.
The transgenic non-human animal of claim 9, wherein the isoenyzme is a protein selected from the group consisting of any one of SEQ ID NOS: 15-25 or an analogue thereof having at least 50% / 75% sequence identity / similarity. 
Transgenična neljudska životinja u skladu s patentnim zahtjevom 9, naznačena time što je izoenzim protein, kojeg se bira iz skupine koju čine bilo koji od SEQ ID NO: 15-25.
When working with biological fluids containing cells, cell debris, and the like it is preferred to first filter and/or ultracentrifuge the fluid to remove these particulate contaminants. 
Kada se radi sa biološkim tekućinama koje sadrže stanice, stanično ostatke i sl., poželjno je najprije filtirati i/ili ultracentrifugirati tekućinu kako bi se uklonili navedeni kontaminanti.
The electromagnetic relay assembly of claim 2 wherein the spring arms comprise first spring means, the first spring means for damping contact vibration intermediate the contacts when switching from the open position to the closed position. 
Elektromagnetski relejni sklop u skladu s patentnim zahtjevom 2, naznačen time što krakovi opruge sadrže prvu oprugu, gdje prva opruga prigušuje vibriranje kontakata između kontakata prilikom preklapanja iz otvorenog položaja u zatvoreni položaj.
A communication device as described in embodiment 18, wherein the communication device is adapted, on receipt of update information, to break an existing network connection and to make a new network connection in accordance with updated selection rules. 
Komunikacioni uređaj prema zahtjevu 18, pri čemu je komunikacioni uređaj prilagođen tako da kada primi informacije o ažuriranju, onda raskine postojeću mrežnu konekciju u skladu sa ažuriranim pravilima izbora.
The use of microcapsules with a polymeric wall according a suitable combination of claims 1 to 29 or produced according a suitable combination of claims 30 to 40 in an agrochemical formulation characterized in that the microencapsulated material is tebuconazole, where the oil phase contains a customary agricultural solvent of the type substituted N-alkyllactam or N,N-dimethylalkylamide. 
Mikrokapsule prema patentnim zahtjevima 1 do 27, naznačene time, što je mikroinkapsulirani materijal tebukonazol, pri čemu uljna faza unutar mikrokapsula sadrži uobičajeno poljoprivredno otapalo tipa supstituiranog N-alkillaktama ili N,N-dimetilalkilamida. Mikrokapsule prema patentnim zahtjevima 1 do 27, naznačene time, što je mikroinkapsulisani materijal fluroksipir.
The system according to claim 8, further comprising at least one illuminating device illuminating the volume of the aqueous solution. 
Sustav prema zahtjevu 5 ili 6, naznačen time da nadalje sadrži barem jednu uređaj za osvjetljavanje (16) koja osvjetljava volumen vodene otopine.
parsing the signal frame from the demodulated signal; and 
Dodlaljivanje simbola PLP-a okviru signala i
a discharge pump installed within the storage tank to discharge the LNG to the outside of the cargo tank; and 
prvu struju otparenog plina, koju se dobiva iz ukapljenog prirodnog plina u spremniku za teret (11), te ispušta iz spremnika za teret (11);
In one preferred embodiment, R1 is selected from the group consisting of H, halogen, C1-C6alkoxy, CF3, and OCF3. 
Spoj prema zahtjevu 1 ili 2 naznačen time da R, je odabran iz skupine koja sadrži H, halogen.
The compound for use according to claim 7 wherein the hemoglobinopathies are B-thalassemia or sickle cell anemia. 
Spoj za upotrebu prema zahtjevu 7 naznačeno time da su hemoglobinopatije B-talasemija ili anemija srpastih stanica.
When the finishing layer does not run parallel to the substrate layer, the tube system preferably runs substantially parallel to the finishing layer in order to obtain the highest possible efficiency in heat absorption by the fluid. 
Uređaj prema bilo kojem od zahtjeva 1-9, naznačen time da je na podlozi predviđena mreža koja se proteže uglavnom paralelno s nosećim slojem; pri čemu je sustav cijevi spojen na mrežu.
VLP according to at least one of the above claims, wherein the VLP is prepared for oral, parenteral or intravenous administration and in particular for intravenous administration. 
Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, pri čemu se virusu slična čestica (VLP) primenjena intravenozno.
—R3=a cyclic hydrocarbon having 5 or 6 carbon atoms, 
-R3 = ciklički ugljikovodik s 5 do 6 atoma ugljika.
that the press-on portion is formed as a mechanism which, when the lock-up body is compressed, ensures that the lock-up body is positioned with one extremity against a support surface; 
- dio na pritisak (15) kao mehanizam koji, kada je tijelo za zaključavanje komprimirano, omogućava da je to tijelo za zaključavanje smješteno s jednim ekstremitetom na potpornoj površini (21);
The method according to claim 5, wherein the periodate oxidation is performed in a solution with an initial glycosaminoglycan concentration of about 10-20% w/v. 
(ii) uotopini s početnom koncentracijom glikozaminoglikana od 10(+1)% do 20(+2)% mas/v;
is (C1-C4)-alkyl is (C1-C4)-alkyl is reacted in an inert solvent, optionally in the presence of a suitable base, with a compound of the formula (III) H2N—R3 (III) 
R'* je (C,-C,)-alkil, T' je (C,-C,)-alkil, T? je (C,-C,)-alkil, reagira u inertnom otapalu, proizvoljno u prisutnosti odgovarajuće baze, sa spojem s formulom (III)
The mixture was left over night at room temperature. 
Mješavina je ostavljena na sobnoj temperaturi preko noći.
The pharmaceutical composition according to any of claims 1 - 6, wherein the pharmaceutical composition provides a width at 50% of the height of a mean plasma concentration/time curve of the metformin from about 1.0 to about 10 hours or a width at 25% of the height of mean plasma concentration/time curve of the metformin from about 0.25 to about 14 hours. 
Farmaceutski sastav sukladno bilo kojem od zahtjeva 1 - 6, pri čemu farmaceutski sastav osigurava širinu za 50% krive srednja koncentracija u plazmi/vrijeme metformina od oko 0.25 do oko 14 sati.
The composition for use according to claim 2, wherein the crystalline structure (S)-PG (form SC-3) is characterized by one or more of the following: 
Kristalna struktura kako je definirano u zahtjevu 4 naznačena time da ima jedno ili više od slijedećeg:
Also, with a premodeled air-tight covering, it is possible by virtue of the elasticity thereof to permit deviating configurations, such as rims, ribs, small channels, stiffenings, and the like. 
Također, s HR P20070275 T3 prethodno oblikovanim neprodušnim pokrovom, moguće je da se pomoću njegove elastičnosti spriječe nepoželjne konfiguracije, kao što su rubovi, rebra, mali kanali, zadebljanja, i slično.
The method of claim 1 wherein the mixed mode chromatography resin is a Capto™ MMC mixed mode chromatography resin or Capto™ Adhere mixed mode chromatography resin. 
Postupak sukladno zahtjevu 1, naznačen time da je smjesa miješane kromatografske smole CaptoTM MMC mješovita kromatografska smola ili CaptoTM Adhere mješovita kromatografska smola.
A method for making the crystalline form in accordance with claim 1 or 2, said method comprising the following steps: 
Postupak za izradu kristaliničnog oblika u skladu sa zahtjevom 1 ili 2, naznačen time, da navedeni postupak sadrži slijedeće korake:
The liquefied gas treatment system according to claim 7, further comprising BOG consuming means configured to receive and uses BOG that is compressed while passing through a part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što dodatno uključuje element za potrošnju otparenog plina, koji prima i upotrebljava otpareni plin, koji se komprimira prilikom prolaska kroz dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
#17. A method according to aspect #16, wherein the amount of base added is at least sufficient to neutralise at least 90% of the carboxylic acid groups in the polycarboxylic acid polymer. 
Postupak za koji se traži zaštita patentom u patentnom zahtjevu 13, pri čemu je dodana količina baze najmanje dovoljna da neutralizira bar 90% skupina karboksilne kiseline u polimeru polikarboksilne kiseline.
The process of paragraph 1, wherein said first base is selected from the group consisting of triethylamine, 1,5-diazabicyclo[4,3,0]non-5-ene 1,4-diazabicyclo[2,2,2]octane, and 1,8-diazabicyclo[5,4,0]undec-7-ene, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedenu prvu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.0]non-5-en, 1,4-diazabiciklo[2.2.2]oktan i 1,8-diazabiciklo[5.4.Q0]undec-7-en, te smjese 2 ili više njih.